


PHARMACEUTICAL 2021



## ANAPTYSBIO INC Rank 23 of 409







RealRate

PHARMACEUTICAL 2021



ANAPTYSBIO INC Rank 23 of 409

The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 170% points. The greatest weakness of ANAPTYSBIO INC is the variable Research and Development, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 517% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	396,561
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,821
Liabilities, Non-Current	0
Other Assets	18,208
Other Compr. Net Income	-342
Other Expenses	0
Other Liabilities	0
Other Net Income	3,948
Property and Equipment	1,783
Research and Development	80,025
Revenues	75,000
Selling, General and Administrative Expense	18,854

Output Variable	Value in 1000 USD
Assets	416,552
Liabilities	19,821
Expenses	98,879
Stockholders Equity	396,731
Net Income	-19,931
Comprehensive Net Income	-20,102
Economic Capital Ratio	163%

